The Effect of Delayed Chemotherapy on the Decrease of CA125 in Epithelial Ovarian Cancer During Coronavirus Disease Pandemic in 2020

Yi, Qiang; Ran, Yu; Li, Cong

doi:10.2147/cmar.s289773

Cited by 4 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pyeon et al 8 reported that delaying palliative chemotherapy had no adverse effects on the survival of patients with recurrent ovarian cancer. Delayed chemotherapy had no effect on the chemotherapy efficacy and declined levels of cancer antigen (CA) 125 during the coronavirus disease 2019 (COVID-19) pandemic 9 .…”

Section: Introductionmentioning

confidence: 99%

Impact of Treatment Delay on the Prognosis of Patients with Ovarian Cancer: A Population-based Study Using the Surveillance, Epidemiology, and End Results Database

Zhao,

Chen,

Zhang

et al. 2024

J. Cancer

View full text Add to dashboard Cite

Purpose: This study aimed to assess the impact of treatment delay on prognosis in patients with ovarian cancer. Methods: A retrospective analysis of patients with ovarian cancer in the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2015 was performed. Chi-square tests were used to assess baseline differences. The Kaplan-Meier method was used to evaluate the effect of different treatment intervals on survival outcomes in patients. Cox regression analyses were used to identify independent factors associated with ovarian cancer prognosis. Results: Of the 21,590 patients included, 15,675 (72.6%), 5,582 (25.9%), and 333 (1.54%) were classified into the immediate-treatment (<1 month after diagnosis), intermediate-delay (1-2 month delayed), and long-delay groups (≥3 months delayed), respectively. The 5-year probability of overall survival (OS) was 61.4% in the immediate-treatment group, decreasing to 36.4% and 34.8% in the intermediate- and long-delay groups, respectively. Similar survival differences were also reflected in cancer-specific survival (CSS), with 5-year CSS probabilities of 66.7%, 42.6%, and 41.8% in the aforementioned groups, respectively. Patients in the intermediate-delay group showed poorer OS (adjusted hazard ratio [HR], 1.06; 95% confidence interval [CI], 1.02-1.11; p=0.006) and CSS (adjusted HR, 1.06; 95% CI, 1.01-1.11; p=0.012) than immediate-treatment group. Conclusions: Patients with delayed treatment had poorer OS and CSS. The patient's waiting time from diagnosis to initial treatment should be within 1 month.

show abstract

Section: Introductionmentioning

confidence: 99%

Impact of Treatment Delay on the Prognosis of Patients with Ovarian Cancer: A Population-based Study Using the Surveillance, Epidemiology, and End Results Database

Zhao,

Chen,

Zhang

et al. 2024

J. Cancer

View full text Add to dashboard Cite

show abstract

The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer

Steventon,

Man,

Nicum

et al. 2024

The Oncologist

View full text Add to dashboard Cite

Introduction Chemotherapy forms the cornerstone of systemic treatment for advanced ovarian cancer, extending overall survival; however, drug-related toxicity can lead to treatment delays, potentially diminishing treatment efficacy. This study evaluated the impact of treatment delays on all-cause mortality of patients with ovarian cancer, to better inform decisions on patient management. Methods This retrospective, population-based cohort study included 1517 women with advanced-stage ovarian cancer, receiving first-line adjuvant or neoadjuvant chemotherapy in 2014 and 2015. The frequency of inter-cycle delays >7 days was calculated using drug administration dates. Kaplan-Meier estimates were used to compare 2-year overall survival (OS) between patients who were delayed and those treated to schedule. Cox proportional hazards regression was used to investigate the impact of treatment delay on all-cause mortality. Inverse probability of treatment weighting propensity scores were used to adjust for confounding variables. Results Delays >7 days occurred in 35.3% of patients. Two-year OS probability was 62.7% in patients who experienced treatment delays >7 days (95% CI, 58.7-66.9) compared to 69.1% in those treated to schedule (95% CI, 66.2-72.0). Delays were not significantly associated with all-cause mortality when adjusted for confounders (HR 1.00 95% CI, 0.83-1.20, P = .9). Conclusions Delays to chemotherapy treatment were not significantly associated with worsened survival in patients with advanced-stage ovarian cancer. These results can inform clinical decision making that prioritize toxicity management and quality of life for those treated with chemotherapy.

show abstract

Cancer Patients’ Health Related Quality of Life (HRQoL) and Its Predictor Factors during the COVID-19 Pandemic: A Cross-sectional Survey Study in China

Sun

Peng

Liu

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective To evaluate Chinese cancer patients’ health related quality of life and its predictor factors during the COVID-19 pandemic. Method We conducted an online cross-sectional survey study among Chinese cancer patients in 2020 around China by utilizing the validated Mandarin version of COVID-19 IHRQOL questionnaire. Results 387 patients participated in this survey, in which 283(72.9%) patients worried the pandemic’s impact on their cancer care, 69% feared getting infected by COVID-19. 30.7% and 17.3% patients had experienced depression and social isolation. More than 80% patients reported perceived benefits such as feeling more grateful. 26.3% patients reported financial hardship and 44.9% reported cancer care disruption. Multivariate analyses showed that more financial hardship was significantly associated with higher level of COVID-19 specific distress (p < 0.001). Conclusion Addressing health care services disruption and financial hardship, as well as promoting functional social support might help Chinese cancer patients acquire better HRQoL during the pandemic.

show abstract

The Effect of Delayed Chemotherapy on the Decrease of CA125 in Epithelial Ovarian Cancer During Coronavirus Disease Pandemic in 2020

Cited by 4 publications

References 18 publications

Impact of Treatment Delay on the Prognosis of Patients with Ovarian Cancer: A Population-based Study Using the Surveillance, Epidemiology, and End Results Database

Impact of Treatment Delay on the Prognosis of Patients with Ovarian Cancer: A Population-based Study Using the Surveillance, Epidemiology, and End Results Database

The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer

Cancer Patients’ Health Related Quality of Life (HRQoL) and Its Predictor Factors during the COVID-19 Pandemic: A Cross-sectional Survey Study in China

Contact Info

Product

Resources

About